Niclosamide

Territorial Availability: Available through Bertin Technologies only in France

Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.

Special Advice: Dangerous Good in said quantity, not available for sale.

• Synonyms
  • 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-benzamide
• Correlated keywords
  • mTORC MCF7 EGFPLC3 Hep-G2 COVID19 SARSCoV2 SARS-CoV2 SARSCoV MERSCoV DU-145 Salicylanilide BAY2353 BAY Bayer 2353 Bayluscid Cestocid Cestocide Devermin Devermine Fedal-Telmin Fenasal HL 2447 HL2447 Helmiantin Iomesan Lintex Mansonil Mato NSC178296 Nasemo Niclocide Niclosamide Phenasal Radeverm Ruby Sagimid Sulqui Tredemine Utosamide Vermitid Vermitin WR 46234 WR46234 Yomesan Zestocarp
• Product Overview:
  Niclosamide is an anthelmintic that disrupts mitochondrial metabolism in parasitic worms and animal models.{29804,17472,27785} It inhibits STAT3 transcriptional activity (IC50 = 0.25 ?M in a reporter assay) and stimulates autophagy by reversibly inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling in MCF-7 cells expressing EGFP-LC3.{17472,18706} It completely inhibits phosphorylation of ribosomal S6 kinases (S6K) when used at a concentration of 3 µM.{17472} Niclosamide (1 µM) induces mitochondrial uncoupling, decreasing cellular ATP concentrations and increasing the ratio of ADP to ATP in HepG2 cells, and activates AMP-activated protein kinase (AMPK) in NIH3T3 cells.{27785} It also increases lipid oxidation by 5-fold in HepG2 cells. Niclosamide (5 and 10 µM) inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2) and Middle East respiratory syndrome CoV (MERS-CoV).{57523} It prevents high-fat diet-induced hepatic steatosis and insulin resistance and improves glycemic control in db/db mice when administered at a dose of 125 mg/kg per day.{27785} Niclosamide also inhibits proliferation and colony formation of DU145 prostate cancer cells, which have constitutively active STAT3 (IC50s = 0.7 and 0.1 µM, respectively).{18706}